Synopsys Inc. filings document the regulatory record for a Nasdaq-listed engineering software company whose common stock trades under SNPS. The company’s disclosures cover operating and financial results, capital allocation actions such as stock repurchase authorizations and accelerated share repurchase agreements, and material-event reports tied to governance, executive roles, and organizational changes.
Proxy and annual meeting materials describe board elections, shareholder voting matters, executive compensation, equity incentive plan approvals, and corporate governance practices. Recent Form 8-K filings also document restructuring actions following the completed Ansys acquisition, amendments to prior governance disclosures, registered common stock details, exhibits, and risk-oriented statements associated with forward-looking business actions.
SYNOPSYS INC (SNPS) reported that Janet Lee, GC & Corporate Secretary, exercised 2,283 Restricted Stock Units into an equal number of shares of common stock on September 11, 2026. In connection with this vesting, 993 shares of common stock were withheld by Synopsys to satisfy tax withholding obligations, at a price of $397.38 per share, as approved by the Compensation Committee. Following the derivative transaction, Lee continues to hold 4,565 Restricted Stock Units directly, and no Rule 10b5-1 trading plan is reported.
SYNOPSYS INC (SNPS) reported that officer Janet Lee, General Counsel & Corporate Secretary, exercised a restricted stock unit award on September 1, 2026. 699 restricted stock units converted into the same number of shares of common stock, while 304 shares were withheld by Synopsys to cover tax withholding obligations related to this vesting. Following the exercise, 1,398 restricted stock units remained outstanding for the reporting person. No Rule 10b5-1 trading plan is reported in connection with these transactions.
SYNOPSYS INC (SNPS) director and president & CEO Ghazi Sassine acquired 27 shares of common stock on August 31, 2026 through an acquisition classified as an “other” transaction under the company’s Employee Stock Purchase Plan at a reported price of $360.961 per share, bringing his direct holdings to 76,865 shares.
No transactions were reported under a Rule 10b5-1 trading plan, and no derivative securities were reported in this filing.
SYNOPSYS INC (SNPS) reported that Deputy CFO & CAO Sudhindra Kankanwadi acquired 27 shares of common stock on August 31, 2026 through participation in the Synopsys, Inc. Employee Stock Purchase Plan at a price of $360.961 per share. Following this transaction, the officer directly holds 22,717 shares of Synopsys common stock, and no Rule 10b5-1 trading plan is reported.
SYNOPSYS INC (SNPS) reported that Chief Revenue Officer Michael Ellow acquired 27 shares of common stock on August 31, 2026 through an acquisition of stock under the Synopsys, Inc. Employee Stock Purchase Plan at a price of $360.96 per share. After this transaction, he held 2,612 shares directly and 16 shares indirectly through a family trust. No Rule 10b5-1 trading plan is reported for these transactions.
SYNOPSYS INC (SNPS) reports that Executive Chair Aart de Geus exercised and sold company equity over August 31 and September 1, 2026. He exercised in total 49,641 non-qualified stock options at an exercise price of $135.88 per share to acquire the same number of common shares, then sold 25,000 shares at a weighted average price of $441.7646 and 24,641 shares at a weighted average price of $419.4401 in open-market transactions. He also acquired 22 shares through the Synopsys Employee Stock Purchase Plan. All reported transactions were effected under a Rule 10b5-1 trading plan adopted October 14, 2025. Indirect holdings after these transactions include 308,791 shares held by a Family Trust and 14,500 shares held by a Partnership.
For SYNOPSYS INC (SNPS), Executive Chair Aart de Geus reported an option exercise and related share sale. On 2026-08-28 he exercised 25,000 Non-Qualified Stock Options at an exercise price of $135.88 per share, acquiring an equal number of SNPS common shares. On the same date, he sold 25,000 common shares at a weighted average price of $445.5502 per share in multiple transactions. Following these transactions, he directly held 49,641 shares, and indirectly held 308,791 shares through a Family Trust and 14,500 shares through a Partnership. The filing states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 14, 2025.
Synopsys Inc. officer and director Aart De Geus reported a proposed sale of 74,641 common shares, with an aggregate market value of $34,472,945.85 and an approximate sale date of August 28, 2026. The notice lists UBS Financial Services Inc. as broker. It states that De Geus acquired the shares from the issuer on August 28, 2026, through exercise of a stock option, with cash payment, and gives October 14, 2025, as the Rule 10b5-1 plan adoption or instruction date.
Synopsys, Inc. (SNPS) reported strong growth for the quarter ended July 31, 2026, with total revenue of $2.48 billion, up from $1.74 billion a year earlier, and net income attributed to Synopsys of $545.8 million versus $242.5 million. Diluted EPS from continuing operations rose to $2.84 from $1.50. Growth was driven by Design Automation revenue of $2.00 billion and Design IP revenue of $473.9 million, with Ansys-branded products contributing a rising share.
For the first nine months, revenue reached $7.16 billion compared with $4.80 billion, while net income declined to $627.3 million from $884.8 million, reflecting substantially higher $1.21 billion of acquired intangible amortization and $236.3 million in restructuring charges tied to a 2026 plan estimated at $425–500 million. Synopsys also recorded a $380.5 million net pre-tax gain on the sale of its Processor IP business.
Cash flow from operations for the nine months improved to $2.30 billion from $878.9 million, and cash, cash equivalents and restricted cash were $3.61 billion. The company carries $10.0 billion of Senior Notes outstanding after fully repaying a $4.3 billion term loan. Backlog (contracted but unsatisfied performance obligations) was about $10.9 billion, including $1.9 billion of non-cancellable FSA commitments.
SYNOPSYS, INC. (SNPS) filed an amendment to update its disclosure about a previously approved restructuring plan. The Board originally approved the restructuring plan on November 9, 2025, and on August 21, 2026, approved updated estimates reflecting higher restructuring costs.
Synopsys now estimates it will recognize pre-tax charges ranging from $425 million to $500 million to its GAAP financial results. These charges consist primarily of severance and other one-time termination benefits, as well as costs related to certain site closures as part of its global site strategy. The company characterizes these as forward-looking estimates subject to risks, including possible changes in the size, components and timing of the expected costs and Synopsys’ ability to realize the benefits of the restructuring.